LifeMD, Inc. Shareholders Who Lost Money on Their Investment are Encouraged to Contact Johnson Fistel about the Class Action Lawsuit

SAN DIEGO, August 28, 2025 – Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of LifeMD, Inc. (NASDAQ: LFMD) (“LifeMD” or the “Company”). The lawsuit seeks to recover losses on behalf of investors who purchased the Company’s securities between May 7, 2025 and August 5, 2025.

If you purchased LifeMD securities and suffered losses, you have until October 27, 2025 to seek appointment as lead plaintiff.

According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.